Navigation Links
Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica
Date:9/6/2007

on results let our customers and potential customers know that, as a corporation, we are dedicated to developing, implementing, and maintaining the highest quality standards for the protection of those who use our raw materials and finished products."

About Sabila Industrial

Sabila Industrial, S.A. is a wholly owned subsidiary of Carrington Laboratories, Inc. dedicated to producing raw materials for oral care, wound care, and consumer products manufactured by Carrington and GelSite(R) for DelSite Biotechnologies, Inc. All naturally derived polymeric raw materials are produced under the FDA's cGMP standards for use in human drugs. An injectable biologic raw material to treat fibrosarcoma in companion animals is produced by Sabila under USDA biologic regulations. Sabila Industrial, S.A. operates in a duty-free zone with an adjacent farm, Finca Sabila, which is certified organic by an agency of the Costa Rican government and recognized by the USDA and the European Union.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit '/>"/>

SOURCE Carrington Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and ... production capability to serve biotechnology pharmaceutical clients. A ... continues to drive Nitto Avecia to enhance synthesis ... , In Fall 2014, Nitto Avecia first ... its Milford, MA facility, which is recognized as ...
(Date:4/30/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) a ... biosimilar therapeutics including high value and difficult to ... previously announced underwritten public offering of 6,750,000 shares ... price of $15.50 per share. This includes the ... option to purchase up to 750,000 additional shares ...
(Date:4/30/2015)... Available in select spas in ... , Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield Cream provides ... battling the weakening threat of inflammaging, aging directly ... with star ingredient GLYCOSEA, a complex of restructuring ... of soothing minerals and trace elements. GLYCOSEA works ...
(Date:4/29/2015)... Washington, and BALTIMORE, Maryland, USA (PRWEB) April 29, 2015 ... event for photonics, optical sensing, and imaging on the ... place for government program managers, researchers, applications developers, and ... technology of sensing and imaging for multiple applications. , ... defense and security, and commercial and scientific sensing and ...
Breaking Biology Technology:Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4
... Virobay, Inc., a privately held ... protease inhibitors for the treatment of autoimmune diseases, ... showing that one of the company,s spectrum-selective cathepsin ... bone cancer pain.  Virobay has a series of ...
... 14, 2011 A new retrospective ... etexilate mesylate) capsules 150mg twice daily reduced the ... warfarin in patients with non-valvular atrial fibrillation (NVAF) ... (sHF), with no significant interaction for major bleeding ...
... inVentiv Health, Inc., offering best-in-class clinical, commercial ... today that it has been selected by the ... operations support, as well as recruiting and sales ... for Type 2 diabetes. inVentiv ...
Cached Biology Technology:Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model 2Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model 3New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 2New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 3New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 4New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 5New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 6New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 7New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 8inVentiv Health Selected to Provide Sales Operations Support for Santarus 2inVentiv Health Selected to Provide Sales Operations Support for Santarus 3inVentiv Health Selected to Provide Sales Operations Support for Santarus 4
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... issued today, co-authored by the Wildlife Conservation Society (WCS) ... the 25 most endangered turtle species from around the ... five individuals. Decimated by illegal hunting for both ... many turtle species will go extinct in the next ...
... in cancer treatment, destroy not only cancer cells but ... Consequently, after surviving cancer many female patients are confronted ... relationship between infertility and chemotherapeutic agents has been assumed, ... , Scientists from the research group of Prof. Volker ...
... Calif. and STATE COLLEGE, Pa., Feb. 22, 2011 ... GeneMarker HID forensics software will power the data analysis ... for human identification. The incorporated software will enable the ... standardized formats compatible with human identification database search systems. ...
Cached Biology News:Shellshock: New report lists 25 most endangered turtle species 2Why chemotherapy causes more infertility in women than in men 2Why chemotherapy causes more infertility in women than in men 3SoftGenetics to Supply Forensic Analysis Software for IntegenX's Automated DNA Identity Profiling System 2SoftGenetics to Supply Forensic Analysis Software for IntegenX's Automated DNA Identity Profiling System 3
... performance agitation and temperature control for microbiology ... wells independently and is suitable for DASGIP ... working volume. Its temperature ranges from approximately ... well is equipped with an individual electrical ...
... analyzes and reports the data from any one ... a chart recorder. The final data is sent ... end-point selection is automatic for Systolic, Mean, Heart ... The user is always in the position to ...
... DNA microarrays designed for your specific applications ... Paraflo microfluidic synthesis platform. Thousands of customer ... LC Sciences can provide assistance with custom ... part of our comprehensive Custom DNA Microarray ...
... RNA aptamer screening and binding optimization and ... microfluidic on-chip synthesis platform. These microarrays are ... Aptamer Microarray Service. Probe Content ... contains greater than 1500 known aptamer sequences. ...
Biology Products: